Dysregulated Brain Protein Phosphorylation Linked to Increased Human Tau Expression in the hTau Transgenic Mouse Model.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
08 Jun 2022
Historique:
received: 11 05 2022
revised: 02 06 2022
accepted: 07 06 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 28 6 2022
Statut: epublish

Résumé

Altered protein phosphorylation is a major pathologic modification in tauopathies and Alzheimer's disease (AD) linked to abnormal tau fibrillar deposits in neurofibrillary tangles (NFTs) and pre-tangles and β-amyloid deposits in AD. hTau transgenic mice, which express 3R and less 4R human tau with no mutations in a murine knock-out background, show increased tau deposition in neurons but not NFTs and pre-tangles at the age of nine months. Label-free (phospho)proteomics and SWATH-MS identified 2065 proteins in hTau and wild-type (WT) mice. Only six proteins showed increased levels in hTau; no proteins were down-regulated. Increased tau phosphorylation in hTau was detected at Ser199, Ser202, Ser214, Ser396, Ser400, Thr403, Ser404, Ser413, Ser416, Ser422, Ser491, and Ser494, in addition to Thr181, Thr231, Ser396/Ser404, but not at Ser202/Thr205. In addition, 4578 phosphopeptides (corresponding to 1622 phosphoproteins) were identified in hTau and WT mice; 64 proteins were differentially phosphorylated in hTau. Sixty proteins were grouped into components of membranes, membrane signaling, synapses, vesicles, cytoskeleton, DNA/RNA/protein metabolism, ubiquitin/proteasome system, cholesterol and lipid metabolism, and cell signaling. These results showed that over-expression of human tau without pre-tangle and NFT formation preferentially triggers an imbalance in the phosphorylation profile of specific proteins involved in the cytoskeletal-membrane-signaling axis.

Identifiants

pubmed: 35742871
pii: ijms23126427
doi: 10.3390/ijms23126427
pmc: PMC9223516
pii:
doi:

Substances chimiques

tau Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : La Caixa Foundation
ID : LCF/PR/HR19/52160007
Organisme : Instituto de Salud Carlos III
ID : PT17/0019/009

Références

Alzheimers Dement. 2021 Jan;17(1):115-124
pubmed: 33075193
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Neuroscience. 2021 Oct 30;:
pubmed: 34757172
Brain Res Bull. 2016 Sep;126(Pt 3):238-292
pubmed: 27615390
FEBS J. 2009 Jun;276(12):3177-98
pubmed: 19438722
Trends Biochem Sci. 2000 Dec;25(12):596-601
pubmed: 11116185
Int J Mol Sci. 2022 Jan 10;23(2):
pubmed: 35054902
Proteomics. 2013 Apr;13(8):1292-305
pubmed: 23335269
Front Mol Neurosci. 2014 May 13;7:42
pubmed: 24860424
Mol Cell Proteomics. 2007 Sep;6(9):1638-55
pubmed: 17533153
Mol Neurodegener. 2018 Jan 16;13(1):2
pubmed: 29338754
Hum Mol Genet. 2015 Jan 15;24(2):540-58
pubmed: 25231903
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
J Clin Pathol. 2019 Nov;72(11):725-735
pubmed: 31395625
Brain. 2020 Sep 1;143(9):2803-2817
pubmed: 32812023
Oncotarget. 2016 Jun 7;7(23):33627-48
pubmed: 27144524
Aging Cell. 2016 Oct;15(5):924-39
pubmed: 27448508
Neuron. 2020 Mar 18;105(6):975-991.e7
pubmed: 31926610
Neurobiol Aging. 2005 Jul;26(7):1015-22
pubmed: 15748781
Proteomics. 2015 Jan;15(2-3):508-519
pubmed: 25332170
J Neuropathol Exp Neurol. 2015 Oct;74(10):975-99
pubmed: 26360374
Mol Neurodegener. 2021 Aug 23;16(1):57
pubmed: 34425874
J Proteome Res. 2008 Sep;7(9):3661-7
pubmed: 18700793
J Neurosci. 2002 Nov 1;22(21):9340-51
pubmed: 12417659
Nat Commun. 2017 Aug 21;8(1):291
pubmed: 28827567
Chem Rev. 2001 Aug;101(8):2209-42
pubmed: 11749371
Brain Pathol. 2018 Nov;28(6):965-985
pubmed: 29396893
Int J Mol Med. 2017 Aug;40(2):271-280
pubmed: 28656226
Nat Rev Mol Cell Biol. 2002 Mar;3(3):177-86
pubmed: 11994738
J Neurosci. 2005 Jun 1;25(22):5446-54
pubmed: 15930395
ACS Chem Neurosci. 2019 Sep 18;10(9):3986-3996
pubmed: 31424205
J Neuropathol Exp Neurol. 2014 Jan;73(1):81-97
pubmed: 24335532
Brain Pathol. 2021 Nov;31(6):e12996
pubmed: 34218486
Methods. 2011 Aug;54(4):370-8
pubmed: 21316455
Int J Mol Sci. 2021 Aug 26;22(17):
pubmed: 34502116
Braz J Psychiatry. 2013;35 Suppl 2:S82-91
pubmed: 24271230
OMICS. 2020 Apr;24(4):216-227
pubmed: 32182160
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
J Proteomics. 2016 Oct 4;148:149-58
pubmed: 27498392
Nat Rev Mol Cell Biol. 2017 Jun;18(6):361-374
pubmed: 28356571
Biochim Biophys Acta. 2005 Jan 3;1739(2-3):251-9
pubmed: 15615643
Neuron. 2007 Feb 1;53(3):337-51
pubmed: 17270732
J Neurosci. 2006 Oct 18;26(42):10636-45
pubmed: 17050703
Neuropathol Appl Neurobiol. 2015 Feb;41(1):59-80
pubmed: 25428793
Prog Biophys Mol Biol. 2009 Sep-Oct;100(1-3):47-56
pubmed: 19523976
Acta Neuropathol. 2020 Apr;139(4):735-771
pubmed: 31907603
Front Neurol. 2021 Jan 07;11:595532
pubmed: 33488497
J Neurochem. 2003 Aug;86(3):582-90
pubmed: 12859672
Neuropathol Appl Neurobiol. 2022 Apr;48(3):e12792
pubmed: 35064600

Auteurs

Isidro Ferrer (I)

Department of Pathology and Experimental Therapeutics, Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, University of Barcelona, 08907 Barcelona, Spain.
Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Calle Feixa Llarga sn, 08907 Barcelona, Spain.

Pol Andrés-Benito (P)

Department of Pathology and Experimental Therapeutics, Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, University of Barcelona, 08907 Barcelona, Spain.
Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Calle Feixa Llarga sn, 08907 Barcelona, Spain.

Karina Ausín (K)

Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, 31192 Pamplona, Spain.

Paz Cartas-Cejudo (P)

Clinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Irunlarrea Street, 31192 Pamplona, Spain.

Mercedes Lachén-Montes (M)

Clinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Irunlarrea Street, 31192 Pamplona, Spain.

José Antonio Del Rio (JA)

Molecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Barcelona Institute for Science and Technology, Science Park Barcelona (PCB), 08028 Barcelona, Spain.
Department of Cell Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Carrer Baldiri Reixac, 08028 Barcelona, Spain.

Joaquín Fernández-Irigoyen (J)

Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, 31192 Pamplona, Spain.

Enrique Santamaría (E)

Clinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Irunlarrea Street, 31192 Pamplona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH